On Thursday, Alchemab Therapeutics Entered A Collaboration With Eli Lilly To Discover, Develop, And Commercialize Up To Five Therapeutics For Amyotrophic Lateral Sclerosis; Alchemab Will Receive An Undisclosed Upfront Payment And Is Eligible To...
On Thursday, Alchemab Therapeutics Entered A Collaboration With Eli Lilly To Discover, Develop, And Commercialize Up To Five Therapeutics For Amyotrophic Lateral Sclerosis; Alchemab Will Receive An Undisclosed Upfront Payment And Is Eligible To...
週四，Alchemab Therapeutics與Eli Lilly達成合作，以發現、開發和商業化多達五種用於肌萎縮側索硬化症的治療藥物；Alchemab將獲得一筆未透露金額的預付款，並有資格...
On Thursday, Alchemab Therapeutics Entered A Collaboration With Eli Lilly To Discover, Develop, And Commercialize Up To Five Therapeutics For Amyotrophic Lateral Sclerosis; Alchemab Will Receive An Undisclosed Upfront Payment And Is Eligible To Receive Milestone Payments, Plus Royalties
在週四，Alchemab Therapeutics與Eli Lilly達成合作，共同發現、開發和商業化多達五種用於治療肌萎縮側索硬化症的藥物；Alchemab將獲得一筆未披露的預付款，並有資格獲得里程碑付款和版稅。
Alchemab's technology platform uses patient samples from individuals with unusually slow rates of disease progression to identify antibodies associated with resilience.
Alchemab的科技平台利用患有異常緩慢疾病進展的患者樣本，識別與抗逆境相關的抗體。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。